FDA RMAT boosts inhaled gene therapy KB707, delivering IL‑2/IL‑12 to lung tumors; early trial shows responses with manageable ...
In an interview on the first-in-human phase 1 study of gintemetostat, Saad Z. Usmani, MD, PhD, detailed the initial safety ...
For many patients undergoing cancer treatment, hair loss is one of the most distressing adverse effects. In an effort to take ...
New targeted drugs transform HER2, ROS1 and ALK lung cancer care, boosting brain response and survival—while precision choices still matter.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results